[go: up one dir, main page]

BRPI0817270A2 - formas sólidas de 2-amino-3-(4-(2-amino-6((r)-1-1(4-cloro-2-(3-metil-1h-pirazol-1-il)) fenil-2,2,2-triflúor etóxi) pirimidin-4-il) fenil) propanoato de (s)-etila e processos de seu uso - Google Patents

formas sólidas de 2-amino-3-(4-(2-amino-6((r)-1-1(4-cloro-2-(3-metil-1h-pirazol-1-il)) fenil-2,2,2-triflúor etóxi) pirimidin-4-il) fenil) propanoato de (s)-etila e processos de seu uso

Info

Publication number
BRPI0817270A2
BRPI0817270A2 BRPI0817270A BRPI0817270A BRPI0817270A2 BR PI0817270 A2 BRPI0817270 A2 BR PI0817270A2 BR PI0817270 A BRPI0817270 A BR PI0817270A BR PI0817270 A BRPI0817270 A BR PI0817270A BR PI0817270 A2 BRPI0817270 A2 BR PI0817270A2
Authority
BR
Brazil
Prior art keywords
phenyl
amino
propanoate
pyrazol
pyrimidin
Prior art date
Application number
BRPI0817270A
Other languages
English (en)
Inventor
Perlberg Anett
Zhang Haiming
Stephen Bednarz Mark
C Kanamarlapudi Ramanaiah
Margaret De Paul Susan
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39944300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817270(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of BRPI0817270A2 publication Critical patent/BRPI0817270A2/pt
Publication of BRPI0817270B1 publication Critical patent/BRPI0817270B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0817270-6A 2007-09-28 2008-09-25 Compostos cristalinos de (s)-etil 2-amino-3-(4-(2-amino-6((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1- il)) fenil2,2,2-triflúor etoxi) pirimidin-4-il) fenil) propanoato, sais, e seu processo preparação BRPI0817270B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97584607P 2007-09-28 2007-09-28
US60/975,846 2007-09-28
PCT/US2008/077594 WO2009042733A1 (en) 2007-09-28 2008-09-25 Solids forms of ( s) -ethyl 2-amin0-3- (4- (2 -amino- 6- ( (r) -1- (4-chl0r0-2- o-methyl-ih-pyrazol- 1-yl) phenyl) -2, 2, 2-trifluorethoxy) -pyrimidin-4-yl) phenyl) propanoate

Publications (2)

Publication Number Publication Date
BRPI0817270A2 true BRPI0817270A2 (pt) 2017-06-06
BRPI0817270B1 BRPI0817270B1 (pt) 2022-02-08

Family

ID=39944300

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817270-6A BRPI0817270B1 (pt) 2007-09-28 2008-09-25 Compostos cristalinos de (s)-etil 2-amino-3-(4-(2-amino-6((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1- il)) fenil2,2,2-triflúor etoxi) pirimidin-4-il) fenil) propanoato, sais, e seu processo preparação

Country Status (25)

Country Link
US (2) US8193204B2 (pt)
EP (1) EP2203444B1 (pt)
JP (1) JP5717445B2 (pt)
KR (1) KR101644657B1 (pt)
CN (1) CN101809018B (pt)
AR (1) AR068558A1 (pt)
AU (1) AU2008304439B2 (pt)
BR (1) BRPI0817270B1 (pt)
CA (1) CA2700835C (pt)
CL (1) CL2008002880A1 (pt)
CO (1) CO6270325A2 (pt)
DK (1) DK2203444T3 (pt)
EA (1) EA017275B1 (pt)
EC (1) ECSP10010076A (pt)
ES (1) ES2431928T3 (pt)
IL (1) IL204373A (pt)
MX (1) MX2010003326A (pt)
NZ (1) NZ583808A (pt)
PE (1) PE20090742A1 (pt)
PL (1) PL2203444T3 (pt)
PT (1) PT2203444E (pt)
TW (1) TWI439457B (pt)
UA (1) UA102079C2 (pt)
UY (1) UY31364A1 (pt)
WO (1) WO2009042733A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265495B (zh) 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EA201070059A1 (ru) * 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Композиции, содержащие ингибиторы триптофангидроксилазы
EP2529740A1 (en) * 2007-08-24 2012-12-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
CA2719505A1 (en) * 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
WO2011056916A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
TW201302754A (zh) * 2010-11-05 2013-01-16 Lexicon Pharmaceuticals Inc 3-(4-(胺甲基)-1-(5-甲基-7h-吡咯[2,3-d]嘧啶-4-基)哌啶-4-甲醯胺基)苯基二甲基胺基甲酸酯之固態形式
DK2753306T3 (da) * 2011-10-17 2020-12-14 Lexicon Pharmaceuticals Inc Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
EP3061761A1 (en) 2015-02-24 2016-08-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3275885A1 (en) 2016-07-28 2018-01-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3363798A1 (en) 2017-02-20 2018-08-22 Esteve Química, S.A. Amorphous form of telotristat etiprate
CN109180650A (zh) * 2018-08-28 2019-01-11 湖南华腾制药有限公司 一种氘代色氨酸羟化酶抑制剂的晶型
WO2023192003A1 (en) 2022-04-01 2023-10-05 Tersera Therapeutics Llc Methods of reducing the likelihood of carcinoid heart disease in patients with neuroendocrine tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EP2529740A1 (en) * 2007-08-24 2012-12-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
TW200932729A (en) 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use

Also Published As

Publication number Publication date
EP2203444B1 (en) 2013-07-24
CL2008002880A1 (es) 2009-03-27
EA017275B1 (ru) 2012-11-30
HK1145023A1 (en) 2011-03-25
US20090088447A1 (en) 2009-04-02
AU2008304439B2 (en) 2013-10-17
CA2700835C (en) 2018-01-09
UY31364A1 (es) 2009-03-02
AU2008304439A1 (en) 2009-04-02
JP5717445B2 (ja) 2015-05-13
NZ583808A (en) 2012-01-12
US8193204B2 (en) 2012-06-05
ECSP10010076A (es) 2010-04-30
UA102079C2 (en) 2013-06-10
CN101809018A (zh) 2010-08-18
KR20100063736A (ko) 2010-06-11
PE20090742A1 (es) 2009-07-08
BRPI0817270B1 (pt) 2022-02-08
CN101809018B (zh) 2013-02-06
TW200922934A (en) 2009-06-01
US20130005754A1 (en) 2013-01-03
MX2010003326A (es) 2010-04-09
TWI439457B (zh) 2014-06-01
PT2203444E (pt) 2013-09-12
PL2203444T3 (pl) 2013-12-31
DK2203444T3 (da) 2013-10-28
AR068558A1 (es) 2009-11-18
EA201070410A1 (ru) 2010-10-29
US8653094B2 (en) 2014-02-18
CA2700835A1 (en) 2009-04-02
ES2431928T3 (es) 2013-11-28
WO2009042733A1 (en) 2009-04-02
EP2203444A1 (en) 2010-07-07
IL204373A (en) 2013-12-31
JP2010540551A (ja) 2010-12-24
CO6270325A2 (es) 2011-04-20
KR101644657B1 (ko) 2016-08-01

Similar Documents

Publication Publication Date Title
BRPI0817270A2 (pt) formas sólidas de 2-amino-3-(4-(2-amino-6((r)-1-1(4-cloro-2-(3-metil-1h-pirazol-1-il)) fenil-2,2,2-triflúor etóxi) pirimidin-4-il) fenil) propanoato de (s)-etila e processos de seu uso
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
CY2015016I2 (el) Αναστολεις της κινασης τυροσινης του bruton
BRPI0924183A2 (pt) inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
ATE514695T1 (de) Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
NL2000323A1 (nl) Pyrimidine-derivaten.
BRPI0812563A2 (pt) Metabólitos do inibidor de janus quinase de (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3 ciclopentilpropanonitrila
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
DK2035385T3 (da) Inhibitorer af akt (proteinkinase B)
CU20090141A7 (es) Compuestos 2-amino pirimidina
EP1881773A4 (en) LOCKING CHUCK
ATE512960T1 (de) Pyrimidinderivate
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
SI1869056T1 (sl) Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
DK1928427T3 (da) Hidtil ukendt dosisformulering
BRPI0815754A2 (pt) métodos para preparar compostos à base de 4-fenil-6-(2,2,2-trifluoro-1-feniletóxi)pirimidina
DK2043656T3 (da) Hidtil ukendt medicinsk anvendelse af triazinderivater
BRPI0922908A2 (pt) "composição compreendendo pelo menos dois cicloalquilmeticonas diferentes e uso deste".
EE200600030A (et) Proteiinkinaasi fluorestsents-sond
BRPI0820076A2 (pt) Composto de imidato alta, beta-insaturado e composição pesticida contendo o mesmo
DK1928464T3 (da) Ny parenteral carbamazepin-formulering

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: TERSERA THERAPEUTICS LLC (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.